In particular, major sources of oxidative stress involved in the therapeutic targets of Hyp are derived from CYP2E1 and the downregulation of the expression of antioxidant genes and Nrf2-regulated phase II enzymes occurring in liver disorders. This evidence concerns the gene NFE2L2 and liver disorder.